Dan Killeen

Background

• Partner in Parthenon Capital's Boston office; joined 2021 from Nautic Partners, where he was a Principal covering healthcare services exclusively.
• Earlier: a leadership role at Anthem, Inc. (real payer operating experience, unusual for a PE investor), plus Goldman Sachs Merchant Banking, TA Associates and OpenView. B.A., Dartmouth.
• Promoted to Partner in June 2023; co-CEO Dave Ament publicly credited his "deep expertise in a number of growth areas of healthcare outsourcing and HCIT."

Current focus

• Payer- and provider-adjacent outsourcing and HCIT. Board seats: AArete, Elevate, MRIoA, Momentum, MRO, Nuvem, Smart Data Solutions.
• The pattern across his deals is consistent: recurring-revenue services businesses sitting on a claims or clinical data flow, then bolt automation onto that flow.

What he cares about

• Clean, standardized data as the moat — his own framing on Smart Data Solutions (2021): solutions that "enable payer organizations to have confidence in the claims process."
• Regulatory dislocation as an entry point; on Elevate he framed the thesis around hospitals navigating significant regulatory change.

Recent moves

• Momentum Life Sciences growth investment, 1 July 2026 — his newest deal, and a step sideways into life-sciences patient support.
• Elevate PFS closed 31 July 2025 with Audax; AArete announced June 2025.

Potential sensitivities

• Elevate is co-owned with Audax; he is unlikely to speak freely about governance or exit timing.
• He sits on both payer-side (MRIoA, SDS, AArete) and provider-side (Elevate, MRO) boards. Do not ask him to compare named payer and provider customers.

Three questions to ask

1. Where does denials management stop being labor arbitrage and start earning a software multiple?
2. What did the Audax co-invest structure on Elevate let you underwrite that a solo check would not?
3. Momentum is life sciences, not RCM — new lane for the fund, or a one-off?